In vitro studies have reported significant anti-tumour activity of dacomitinib in gefitinib-resistant lung cancer as well as breast cancer cell lines which are resistant to trastuzumab and lapatinib (a dual HER2 and EGFR inhibitor)37, 38. This evidence concerns the gene ERBB2 and neoplasm.